

AMENDMENTS TO THE CLAIMS:

This listing will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claims 1-7 (Canceled).

Claim 8 (Previously Presented). A method as set forth in claim 21, wherein the substance that acts on guanylyl cyclase A natriuretic peptide receptor and accelerates production of cyclic guanosine monophosphate is a natriuretic peptide.

Claim 9 (Original). A method as set forth in claim 8, wherein the natriuretic peptide is brain natriuretic peptide.

Claim 10 (Original). A method as set forth in claim 8, wherein the natriuretic peptide is brain natriuretic peptide.

Claim 11 (Previously Presented). A method as set forth in claim 8, wherein said substance is in a form of a pharmacologically acceptable salt.

Claims 12-20 (Canceled).

Claim 21 (Currently Amended). A method for treatment of chronic cardiac dysfunction which produces pulmonary congestion, which method does not produce diuretic and hypotensive effects comprising administering a substance that acts on guanylyl cyclase A

natriuretic peptide receptor and accelerates production of cyclic guanosine monophosphate to a subject in need of such treatment in an amount effective for reducing pulmonary congestion, wherein said amount does not produce diuretic and hypotensive effects.

Claims 22-29 (Canceled).